Organon (OGN) Income from Discontinued Operations (2020 - 2021)
Organon (OGN) posted Income from Discontinued Operations of -$4.0 million for Q2 2021, down 200.0% on a QoQ basis from $4.0 million in Q1 2021, and up 90.91% year-over-year from -$2.1 million in Q2 2020.
Powered by 
Analysis
Organon (OGN) Income from Discontinued Operations (2020 - 2021) Analysis & Trends
Organon has reported Income from Discontinued Operations for 2 years, with the latest figure at -$4.0 million in Q2 2021.
- On a quarterly basis, Income from Discontinued Operations rose 90.91% year-over-year to -$4.0 million in Q2 2021; TTM through Mar 2022 was -$4.0 million, a 93.44% increase from a year earlier, with the FY2020 full-year figure at -$96.0 million, down 9.09% from the prior year.
- Income from Discontinued Operations was -$4.0 million for Q2 2021 at Organon, down from $4.0 million in the prior quarter.
- The five-year high for Income from Discontinued Operations was $4.0 million in Q1 2021, with the low at -$44.0 million in Q2 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | - |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | - |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | - |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | 8.00 Mn |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | - |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | - |
| 10 | Organon | 3.58 Bn | 2.45 Bn | 847.00 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2021 | -4.00 Mn |
| Mar 31, 2021 | 4.00 Mn |
| Dec 31, 2020 | -8.00 Mn |
| Sep 30, 2020 | -13.00 Mn |
| Jun 30, 2020 | -44.00 Mn |
| Mar 31, 2020 | -31.00 Mn |